SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trading with heightened volatility as investors weigh President Trumps latest rhetoric on the Iran conflict, which signaled a push to intensify pressure despite mixed signals regarding potential de-escalation timelines. The community is deeply divided, with some traders betting on further supply disruptions and a short squeeze while others view the price action as an overextended reaction driven by speculative headlines.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the focal point of intense market volatility, driven by a highly anticipated Q1 delivery report and community speculation surrounding the upcoming SpaceX IPO. Investors are deeply divided, with bulls pointing to long-term energy and AI growth potential, while bears are aggressively highlighting concerns over declining core vehicle demand and ongoing margin pressures.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is facing significant downward pressure as investors react to escalating geopolitical tensions in the Middle East and a sharp spike in oil prices, fueling fears of inflation and economic instability. Community sentiment remains highly divided and volatile, with market participants debating whether the current selloff is a necessary market correction or a result of artificial manipulation following conflicting leadership signals regarding the conflict.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the online community actively debate the economic and geopolitical implications of the former President's latest address regarding the Iran conflict. The discussion is heavily polarized, with critics pointing to market volatility and concerns over rhetoric, while supporters remain focused on political alignment and ongoing market strategies.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing heightened volatility as investors react to a lack of clear resolution in the ongoing Iran conflict, leading to widespread skepticism toward recent market rallies. Community discourse is dominated by debates over geopolitical instability, the impact of fluctuating oil prices, and deep frustration with what many perceive as market manipulation driven by inconsistent political rhetoric.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense market volatility and increased volume as speculation mounts over a potential acquisition by tech giants like Amazon or SpaceX, with the community actively debating whether current buyout rumors are substantiated or merely a play for leverage. Traders are closely tracking the intersection of GSAT's critical satellite spectrum assets, the long-standing Apple partnership, and the broader space industry land-grab for direct-to-device connectivity.

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Lipocine Inc

Lipocine is currently trending as investors focus on the company's progress with LPCN 1154 for postpartum depression, following the primary endpoint miss in a recent trial. The community is actively debating the company's future development path and potential for strategic partnerships, as stakeholders analyze the stock's long-term viability amid ongoing cash management and pipeline evaluations.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining significant momentum as the community rallies around its upcoming one-year anniversary and anticipation for 4/20 festivities. Investors are actively discussing the project's long-term potential as a culture-driven asset, highlighting its mission to decentralize cannabis advocacy and its persistent organic growth.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is trending due to heightened investor scrutiny regarding its private credit liquidity and redemption policies, alongside market-wide concerns about potential systemic risks in the private debt sector. Community discourse remains polarized, with some investors highlighting the firm's growth in AI data center financing as a long-term catalyst, while others express alarm over redemption caps and comparisons to past financial crises.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is experiencing a significant surge in investor attention following the acquisition of Apium Swarm Robotics and a new strategic partnership with Ukraine's Spetstechnoexport. The community is actively debating the company's long-term defense pipeline, the impact of recent military contract wins within NATO, and the volatility inherent in drone-sector plays as production scales to meet global demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 88.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 359,580 shares of the biotechnology co...

BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 28.5% during the 3rd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - What's Next?

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Should You Buy...

<ul class="summary-bullets"><li>Elevated oil prices and Middle East tensions are keeping traders on the edge.</li><li>Investors are eyeing PMI data and GameStop earnings as near-term catalysts for market direction.</li><li>AI stocks remain in focus amid fresh supply chain concerns and geopolitical scrutiny around chip exports.</li></ul>U.S. stock futures rose early Tuesday, attempting to build on the recovery seen in the previous market session. However, investors remain cautious amid the uncertainty in the Middle East. Traders will also be watching for cues from manufacturing data due this morning and Gamestop earnings later today.&nbsp;Crude oil prices rose on concerns that the Iran conflict could reportedly expand to U.S. allies in the Persian Gulf. This comes even as Iranian lawmakers dismissed the possibility of negotiations with the U.S. As of 4:30 a.m. ET on Tuesday, Dow and S&amp;P 500 futures rose 0.2%, and Nasdaq and Russell 2000 futures were up 0.3%.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘extremely bearish, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bearish’ amid high trading volume.&nbsp;Trending Stocks To Watch Nvidia (NVDA):&nbsp;Following the SMCI crisis, U.S. Senators are reportedly demanding a suspension of the AI bellwether’s GPU export licenses to China and Southeast Asia.&nbsp;Broadcom (AVGO):&nbsp;The chipmaker has reportedly warned that its manufacturing partner, TSMC, is nearing capacity for the year, adding to supply concerns.&nbsp;Oracle (ORCL) and Alibaba (BABA):&nbsp;Reports suggest they have launched significant “agentic AI” initiatives.&nbsp;Alibaba has unveiled a new chip design, while Oracle is said to be embedding AI agents in its cloud-based financial software.&nbsp;Amazon (AMZN):&nbsp;The company has said its Bahrain AWS region has been disrupted by drone activity in the Middle East.&nbsp;Gamestop (GME):&nbsp;The video game retailer reports earnings after the bell today. Investors will be tracking any updates on its Bitcoin treasury or an AI-driven pivot.BioCryst Pharmaceuticals (BCRX): The stock is garnering heavy retail attention following takeover speculation.Applied Optoelectronics (AAOI):&nbsp;The stock was trending on Stocktwits following confirmation of a $53 million order for its 800G data center transceivers.&nbsp;Vertiv Holdings Co. (VRT): The stock is on retail radar after it agreed to acquire Italy-based ThermoKey.&nbsp;And&nbsp;Estee Lauder&nbsp;(EL)&nbsp;is reportedly exploring a merger with Puig. Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Intuitive Machines (LUNR), Micron Technologies (MU), Fastly Inc (FSLY), and The Metals Company (TMC).&nbsp;Other Catalysts To WatchOn the economic front, investors will be tracking the S&amp;P Global Manufacturing &amp; Services PMI at 9:45 am ET. Also, watch out for commentary from&nbsp;Fed Vice Chair for Supervision&nbsp;Michael Barr‘s speech at 6:30 pm ET.&nbsp;On earnings radar, watch out for quarterly reports from&nbsp;Achieve Life Sciences Inc.(ACHV), Greenland Technologies Holding Corp (GTEC), and Huami Corp (ZEPP), before the bell. Meanwhile.&nbsp;Fortress Biotech Inc (FBIO), Durect Corp (DRRX), and Scienture Holdings Inc. (SCNX) are among other companies reporting after market close today.&nbsp; For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Rise Ahead Of PMI Data, Iran Tensions Cap Risk Appetite: Why NVDA, GME, AAOI, BCRX Are Keeping Traders Engaged Today

Data from Stocktwits indicated that retail sentiment has remained bearish on SPY and QQQ for over a week. 

Equity

Data from Stocktwits indicated that retail sentiment has remained bearish on SPY and QQQ for over a week. 


BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen brokerages that are presently covering the stock, MarketBeat...

<ul class="summary-bullets"><li>Retail traders debated the timing and pricing of the buyout, with some expecting an all-cash offer and others speculating about various takeover scenarios.</li><li>Skeptical users noted BioCryst’s history as an acquirer and argued shares would likely trade closer to $14-$15 if firm deal insights existed.</li><li>The company's growth remains anchored by Orladeyo, which generated $601 million in revenue and $214 million in non-GAAP operating profit last year.</li></ul>Shares of BioCryst Pharmaceuticals, Inc. (BCRX) jumped about 11% in after-hours trading on Monday as retail sentiment hit its strongest level of 2026 and volumes doubled, fueling speculation that a U.S. biopharma worth over $15 billion could be circling the company.<a href="https://stocktwits.com/symbol/BCRX">BCRX stock</a> ended over 1% higher at $9.8 on Monday, with shares up 23% over the past year.<h2 class="st-heading-2">Retail Investors Weigh Buyout Odds For BCRX</h2>The renewed takeover buzz followed last week's reports of a Betaville “uncooked” alert, which said that a party interested in BioCryst may be a U.S.-based biopharma firm with a market cap exceeding $15 billion.&nbsp;Among the biotech companies with a market cap between $15 billion and $20 billion are Incyte Corp., Revolution Medicines, Inc., Roivant Sciences Ltd., and Exact Sciences Corp.On Stocktwits, retail sentiment for BCRX has remained ‘extremely bullish’ over the past three months and recently climbed to its strongest level of 2026 amid nearly a 300% surge in message volumes, with investors debating whether the after-hours rally reflected positioning ahead of a potential acquisition.<figure class="image"><img src="https://news.stocktwits-cdn.com/bcrx_ss_png_4999553778.webp" alt="bcrx ss.png" width="967" height="144"><figcaption>BCRX sentiment and message volume as of March 23 | Source: Stocktwits</figcaption></figure>One trader&nbsp;<a href="https://stocktwits.com/SCCT2FL/message/648340880">said</a>, “Somebody knows something. A $10 stock doesn’t just go up 10%+ for nothing after hours.” Meanwhile, another trader&nbsp;<a href="https://stocktwits.com/Iwillbuy/message/648308700">expects</a> a buyout to be announced as soon as Wednesday, in an all-cash offer.Some observers&nbsp;<a href="https://stocktwits.com/tkr/message/648180984">suggested</a> institutional positioning at lower levels supported the takeover narrative, arguing that entry around $9.7 signaled confidence in further upside and the possibility that larger pharmaceutical companies could emerge as bidders.<figure class="image"><img src="https://news.stocktwits-cdn.com/bcrx_sentiment_png_404b898eb7.webp" alt="bcrx sentiment.png" width="973" height="447"><figcaption>BCRX sentiment as of March 23 | Source: Stocktwits</figcaption></figure>Others&nbsp;<a href="https://stocktwits.com/Money_Mane/message/648056955">framed</a> possible price scenarios depending on whether a deal materializes, estimating the shares could reach $16-$18 in a buyout case, trade toward $13-$16 with continued execution, or fall toward $7-$9 if competition increases, with further downside possible if pipeline expectations weaken.&nbsp;However, not all views supported the takeover thesis. One user&nbsp;<a href="https://stocktwits.com/doublebtx/message/648310647">noted</a> that the company’s history suggested it may prefer acting as an acquirer rather than a target, while another argued that if investors had firm takeover insight, the stock would already be trading closer to $14-$15.&nbsp;“If the BO [buyout] speculation (if that even is what is happening) goes away, this certainly could drop back,”&nbsp;<a href="https://stocktwits.com/doublebtx/message/648126797">said</a> one user. “But I would just like to point out that even at these levels, this is not even trading at 4x current revs. So it is certainly not overvalued here with or without BO rumors.”<h2 class="st-heading-2">Orladeyo Anchors Growth Outlook</h2>The takeover speculation surfaced alongside improving pipeline visibility, highlighted earlier this month at the TD Cowen 46th Annual Health Care Conference. CEO Charlie Gayer said the company generated $601 million in revenue last year from Orladeyo, its oral preventive treatment for hereditary angioedema, and $214 million in non-GAAP operating profit.“Orladeyo is still the most differentiated product on the market because it’s the only oral prophylactic on the market today,” Gayer said, adding that half of the patients starting Orladeyo are switching from injectable prophylaxis therapies.The company also highlighted Navenibart, the late-stage hereditary angioedema therapy&nbsp;acquired with Astria, as a key driver of future franchise expansion. It also noted that the composition-of-matter patent protection for Orladeyo extends to 2040.Gayer added that the broader portfolio outlook remains strong: “We’re talking about a portfolio that we see growing at mid-teens in revenue well into the 2030s.”For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

BioCryst Stock Jumps After Hours On Big Pharma Suitor Buzz — Retail Sentiment Hits 2026 Peak

Betaville’s “uncooked” alert from last week flagged potential interest in BioCryst from a U.S.-based biopharma with a market cap above $15 billion.

Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today?

Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 150,000 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 150,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the completion of the...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 150,000 shares of the company's stock in a transaction dated Monday, March 16th. The shares were sold at an...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 13.8% - Here's What Happened

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 13.8% - Should You Buy...

Top Biotech Stocks To Keep An Eye On - March 16th

Danaher, Vertex Pharmaceuticals, Moderna, BioCryst Pharmaceuticals, ImmunityBio, argenex, and Abivax are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.05	--	--	N/A
Q4 '25	$0.05	$1.12	2220.04%	BEAT
Q3 '25	$0.04	$0.06	50.75%	BEAT
Q2 '25	$0.01	$0.02	185.71%	BEAT
Q1 '25	-$0.08	$0.00	100.00%	BEAT

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.